Literature DB >> 23422529

Rocuronium-sugammadex decreases the severity of post-electroconvulsive therapy agitation.

Aysun Postaci1, Civan Tiryaki, Ozlem Sacan, Dilsen Ornek, Merve Kalyoncu, Bayazit Dikmen.   

Abstract

A 51-year-old male patient with a diagnosis of refractory major depressive disorder and unresponsive to antidepressants underwent 8 sessions of electroconvulsive therapy (ECT) every 48 hours. Succinylcholine was used for muscle relaxation until the sixth ECT session, and midazolam was administered for severe emergence agitation that recurred after each session. In the sixth ECT session, rocuronium, 0.4 mg/kg, was used for muscle relaxation and sugammadex, 2 mg/kg, for reversal of muscle paralysis. Subsequently, a clear decrease in post-ECT agitation was observed. We suggest that this combination might be a safe and effective alternative to succinylcholine for post-ECT agitation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23422529     DOI: 10.1097/YCT.0b013e31825de0de

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  4 in total

Review 1.  Anesthetic care for electroconvulsive therapy.

Authors:  Kyoung-Woon Joung; Dong Ho Park; Chang Young Jeong; Hong Seuk Yang
Journal:  Anesth Pain Med (Seoul)       Date:  2022-04-15

2.  The Effects of Rocuronium-sugammadex on Fetomaternal Outcomes in Pregnancy Undergoing Electroconvulsive Therapy: A Retrospective Case Series and Literature Review.

Authors:  Mahmut A Karahan; Evren Büyükfırat; Orhan Binici; Hacer Uyanıkoğlu; Adnan Incebıyık; Mehmet Asoğlu; Nuray Altay
Journal:  Cureus       Date:  2019-06-03

3.  Comparison of emergence agitation between succinylcholine and rocuronium-sugammadex in adults following closed reduction of a nasal bone fracture: a prospective randomized controlled trial.

Authors:  Seok-Jin Lee; Tae-Yun Sung; Choon-Kyu Cho
Journal:  BMC Anesthesiol       Date:  2019-12-16       Impact factor: 2.217

4.  Genomic-Analysis-Oriented Drug Repurposing in the Search for Novel Antidepressants.

Authors:  Mohammad Hendra Setia Lesmana; Nguyen Quoc Khanh Le; Wei-Che Chiu; Kuo-Hsuan Chung; Chih-Yang Wang; Lalu Muhammad Irham; Min-Huey Chung
Journal:  Biomedicines       Date:  2022-08-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.